ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.83
0.43%
US Tech 100
17,184.40
0.63%
S&P 500
5,064.20
0.91%
US Dollar vs CAD
1.36639
-0.02%
Bitcoin
59,381.66
0.44%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Aquestive Therapeutics Inc (AQST)

  7. Aquestive Therapeutics Inc (AQST) News

AQST Aquestive Therapeutics Inc

3.28
0.00 (0.00%)
Pre Market
Last Updated: 03:58:06
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Aquestive Therapeutics Inc AQST NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 3.28 03:58:06
Open Price Low Price High Price Close Price Previous Close
3.28
more quote information »

Recent News

Date Time Source Heading
4/29/202406:00GLOBEAquestive Therapeutics Receives U.S. FDA Approval and Market..
4/25/202407:00GLOBEAquestive Therapeutics to Report First Quarter 2024..
4/12/202415:01GLOBEAquestive Therapeutics to Present Crossover Study Data for..
4/01/202407:00GLOBEAquestive Therapeutics Strengthens Board of Directors with..
3/25/202407:00GLOBEAquestive Therapeutics Announces Closing of Underwritten..
3/19/202420:49GLOBEAquestive Therapeutics Announces Pricing of $75 Million..
3/19/202415:01GLOBEAquestive Therapeutics Announces Proposed Public Offering of..
3/14/202416:23GLOBEAquestive Therapeutics Announces Pivotal Study for Anaphylm™..
3/11/202409:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/11/202409:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/11/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/11/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/11/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/11/202409:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/11/202409:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
3/08/202415:14EDGAR2Form 144 - Report of proposed sale of securities
3/05/202416:12EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
3/05/202416:09EDGAR2Form 8-K - Current report
3/05/202416:05GLOBEAquestive Therapeutics Reports Full Year 2023 Financial..
2/21/202407:00GLOBEAquestive Therapeutics to Report Fourth Quarter 2023..
2/15/202407:00GLOBEAquestive Therapeutics to Present Anaphylm™ (epinephrine)..
2/14/202414:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2/12/202416:02EDGAR2Form S-8 - Securities to be offered to employees in employee..
1/30/202407:00GLOBEAquestive Therapeutics to Participate in Oppenheimer 34th..
12/08/202309:46EDGAR2Form 8-K - Current report
12/05/202307:51EDGAR2Form 8-K - Current report
12/05/202307:00GLOBEAquestive Therapeutics Doses First Patient in Phase 3..
11/10/202307:00GLOBEAquestive Therapeutics to Present Positive Data from..
11/08/202316:04EDGAR2Form 8-K - Current report
11/06/202316:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/06/202316:20EDGAR2Form 8-K - Current report
11/06/202315:37GLOBEAquestive Therapeutics Reports Third Quarter 2023 Financial..
11/02/202307:45EDGAR2Form 8-K - Current report
11/02/202307:00GLOBEAquestive Therapeutics Completes $45 Million Debt..
10/31/202307:00GLOBEAquestive Therapeutics to Report Third Quarter 2023..
10/10/202311:04EDGAR2Form 8-K - Current report
10/09/202307:00GLOBEAquestive Therapeutics Provides Business Update
10/02/202315:18EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/01/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
9/20/202315:39EDGAR2Form 8-K - Current report
9/20/202309:57DJNAquestive Therapeutics Shares Rise 12% on Anaphylm Trial..
9/20/202308:04GLOBEAquestive Therapeutics Reaffirms Timeline and Pathway for..
9/11/202307:00GLOBEAquestive Therapeutics Receives FDA Acceptance of New Drug..
8/23/202307:00GLOBEAquestive Therapeutics to Participate in Two Upcoming..
8/11/202312:14EDGAR2Form 8-K - Current report
8/09/202316:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
8/09/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/09/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/09/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/09/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Your Recent History

NASDAQ
AQST
Aquestive Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved